Publicaciones en colaboración con investigadores/as de Hospital Miguel Servet (30)

2023

  1. Association of Circulating Tumor Cells and Tumor Molecular Profile With Clinical Outcomes in Patients With Previously Untreated Metastatic Colorectal Cancer: A Pooled Analysis of the Phase III VISNÚ-1 and Phase II VISNÚ-2 Randomized Trials

    Clinical Colorectal Cancer, Vol. 22, Núm. 2, pp. 222-230

2022

  1. Association of miR-21 and miR-335 to microsatellite instability and prognosis in stage III colorectal cancer

    Cancer Biomarkers, Vol. 34, Núm. 2, pp. 201-210

  2. Upfront primary tumour resection and survival in synchronous metastatic colorectal cancer according to primary tumour location and RAS status: Pooled analysis of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)

    European Journal of Surgical Oncology, Vol. 48, Núm. 5, pp. 1123-1132

2021

  1. First-Line Biological Agents Plus Chemotherapy in Older Patients with Metastatic Colorectal Cancer: A Retrospective Pooled Analysis

    Drugs and Aging, Vol. 38, Núm. 3, pp. 219-231

  2. Implementation of the Quality Oncology Practice Initiative Program in Spain: First Results and Implications

    JCO oncology practice, Vol. 17, Núm. 8, pp. e1162-e1169

  3. Influence of BRAF and PIK3CA mutations on the efficacy of FOLFIRI plus bevacizumab or cetuximab as first-line therapy in patients with RAS wild-type metastatic colorectal carcinoma and <3 baseline circulating tumour cells: the randomised phase II VISNÚ-2 study

    ESMO open, Vol. 6, Núm. 2, pp. 100062

  4. Management and perception of therapeutic adherence of breakthrough cancer pain by oncologists in Spain

    Revista de la Sociedad Espanola del Dolor, Vol. 28, pp. 19-26

2020

  1. Treatment patterns for metastatic colorectal cancer in Spain

    Clinical and Translational Oncology, Vol. 22, Núm. 9, pp. 1455-1462

2019

  1. Working towards a consensus on the oncological approach of breakthrough pain: A Delphi survey of Spanish experts

    Journal of Pain Research, Vol. 12, pp. 2349-2358

2018

  1. Clinical practice evaluation of opioids induced constipation management in oncologic patients: The EIO-50 project

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii612

  2. Oncologist’s knowledge and implementation of guidelines for breakthrough cancer pain in Spain: CONOCE study

    Clinical and Translational Oncology, Vol. 20, Núm. 5, pp. 613-618

  3. Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancer

    British Journal of Cancer, Vol. 119, Núm. 12, pp. 1464-1470

  4. The quality oncology practice initiative program: Experience in Spain

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii570-viii571

2016

  1. Quality indicators to assure and improve cancer care in Spain using the delphi technique

    JNCCN Journal of the National Comprehensive Cancer Network, Vol. 14, Núm. 5, pp. 553-558

2015

  1. Role of circulating tumor cells as prognostic marker in resected stage III colorectal cancer

    Annals of Oncology, Vol. 26, Núm. 3, pp. 535-541

2014

  1. Social value of a quality-adjusted life year (QALY) in Spain: the point of view of oncologists

    Clinical and Translational Oncology, Vol. 16, Núm. 10, pp. 914-920

2012

  1. First-Line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: The phase III MACRO TTD study

    Onkologie, Vol. 6, Núm. 2, pp. 96-103

  2. First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: The phase III MACRO TTD study

    Oncologist, Vol. 17, Núm. 1, pp. 15-25

  3. Pain in clinical oncology: patient satisfaction with management of cancer pain.

    European journal of pain (London, England), Vol. 16, Núm. 3, pp. 381-389

2010

  1. Parity and the risk of breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers

    Breast Cancer Research and Treatment, Vol. 119, Núm. 1, pp. 221-232